Log In
BCIQ
Print this Print this
 

Bisnorcymserine

  Manage Alerts
Collapse Summary General Information
Company Horizon Pharma plc
DescriptionButyrylcholinesterase inhibitor
Molecular Target Butyrylcholinesterase (BuChE)
Mechanism of ActionCholinesterase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat advanced Alzheimer's disease (AD); Treat Alzheimer's disease (AD)
Regulatory Designation
PartnerQR Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$800.0M

$800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/25/2016

$800.0M

$800.0M

0

Get a free BioCentury trial today